Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Efb-P
- Development stage
- Preclinical
- Lead developer
- University of Bath
- Modality
- Peptides
01
Overview
Efb-P is a novel 12-amino-acid-long peptide (dodecapeptide) derived from the second fibrinogen-binding motif of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb) [PB2549]. It is designed to target P-selectin on platelets, thereby inhibiting the interaction between platelets and leukocytes and preventing the formation of platelet-leukocyte aggregates (PLAs) [PB2549]. Efb-P is being investigated as a potential anti-inflammatory and vasculoprotective treatment for cardiovascular diseases and inflammatory syndromes [PB2549].
- Other names
- Efb-P peptideEfb-derived peptide
02
Targets
SELP (P-selectin)
Beyond the preview
Go deeper on Efb-P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Efb-P.